论文部分内容阅读
目的:研究甲亢低骨量患者131I治疗后干预治疗的效果。方法:对100例甲亢低骨量患者,随机分为两组:A组50例,131I治疗后口服钙尔奇D及罗盖全治疗;B组50例,131I治疗后骨质自然恢复。另设C组50例为正常对照组。于131I治疗前、治疗后3、6及12个月测定A、B两组骨密度(BMD),观察其骨质变化并评价治疗效果。结果:(1)A组随治疗时间延长BMD逐渐升高,具有一定的规律性,腰椎(L2-4)骨密度3个月提高明显(t=-2.111,P=0.04)且12个月时达到与C组无统计学差异(t=-2.290,P=0.202)。(2)B组3个月时腰椎BMD有所降低,12个月时升高明显(股骨颈t=-2.327,P=0.043;腰椎(L2-4)t=-2.798,P=0.000)。(3)6个月时两组腰椎骨密度改善幅度出现统计学差异(t=-2.416,P=0.018),12个月时差异显著(t=-3.259,P=0.002)。结论:131I联合钙尔奇D与罗盖全治疗甲亢低骨量患者,其恢复时间及疗效均用131I治疗,能有效防止骨量的进一步下降及减少骨质疏松症的发生。
Objective: To study the effect of intervention after 131I treatment in patients with low bone mass of hyperthyroidism. Methods: One hundred cases of hyperthyroidism patients with low bone mass were randomly divided into two groups: 50 cases in group A, 100 cases in group A and 50 cases in group B after 131I treatment. The bone recovered naturally after 131I treatment. Another set of C group 50 cases as the normal control group. Bone mineral density (BMD) in group A and group B was measured before 131I treatment and at 3, 6 and 12 months after treatment. The bone changes were observed and the therapeutic effects were evaluated. Results: (1) BMD of group A increased gradually with the prolongation of treatment time, and had certain regularity. BMD of lumbar spine (L2-4) increased significantly at 3 months (t = -2.111, P = 0.04) and at 12 months There was no significant difference between group C and group C (t = -2.290, P = 0.202). (2) The BMD of lumbar spine decreased in group B at 3 months and increased significantly at 12 months (t = -2.327, P = 0.043; t = -2.798, P = 0.000) in lumbar spine (L2-4). (3) At 6 months, there was a statistically significant difference in lumbar BMD between the two groups (t = -2.416, P = 0.018). There was significant difference at 12 months (t = -3.259, P = 0.002). Conclusion: 131I combined with Calcium D and captopril in treatment of hyperthyroidism patients with low bone mass, the recovery time and efficacy were treated with 131I, which can effectively prevent the further decline in bone mass and reduce the incidence of osteoporosis.